Synonym: DOX, Hydroxydaunorubicin hydrochloride
|Related Categories||Antibiotics, Antibiotics A to Z, Antibiotics A-F, Antibiotics by Application, Antineoplastic and Immunosuppressive Antibiotics,|
|mp||216 °C (dec.)(lit.)|
|solubility||H2O: soluble50 mg/mL, clear, orange to red|
|fluorescence||λex 470 nm; λem 585 nm in ethanol|
|suitability||suitable for fluorescence|
Live Chat and Frequently Asked Questions are available for this Product.
Doxorubicin is used as an antitumour antibiotic, to induce apoptosis, and to induce cardiotoxicity in SK-N-MC cells 2,3.
Used to inhibit macromolecular biosynthsis.
Antitumour antibiotic. Effect of adriamycin® on heart mitochondrial DNA;4 Properties.5,6
Inhibitor of reverse transcriptase and RNA polymerase; immunosuppressive agent; intercalates in DNA.
Doxorubicin intercalates DNA and inhibits macromolecular biosynthesis. DNA replication is haulted due to the inhibition of topoisomerase II. It is an inhibitor of reverse transcriptase and RNA polymerase and is an immunosuppressive agent 1.
Bottomless glass bottle. Contents are inside inserted fused cone.
Adriamycin is a registered trademark of RDF Pharmacia & Upjohn S.P.A.
Certificate of Analysis
|Precautionary statements||P201-P305 + P351 + P338-P308 + P313|
|Personal Protective Equipment||Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges|
|Hazard Codes (Europe)||T,Xi|
|Risk Statements (Europe)||45-22-36/38|
|Safety Statements (Europe)||53-45|
Quinolones are a key group of antibiotics that interfere with DNA synthesis by inhibiting topoisomerase, most frequently topoisomerase II (DNA gyrase), an enzyme involved in DNA replication. DNA gyra...
BioFiles 2006, 1.4, 7.
Keywords: Antibiotics, Antitumor agents, Cancer, DNA replication
5. R.J. White et al. Drugs Pharm. Sci. 22, 569, (1984)
6. A. Vigevani, M.J. Williamson Anal. Profiles Drug Subst. 9, 245, (1980)
A novel class of substituted spiro [quinazoline-2,1'-cyclohexane] derivatives as effective PPAR-1 inhibitors: molecular modeling, synthesis, cytotoxic and enzyme assay evaluation. Amin KM, Anwar MM, Syam YM, et al. Acta Pol. Pharm. 70(4), 687-708, (2013)
[A case of recurrent endometrial carcinoma with pleural effusion maintained long SD by pegylated liposomal doxorubicin(PLD)chemotherapy]. Miyamoto Y and Takechi K Gan To Kagaku Ryoho. 40(7), 955-7, (2013)
[Carcinogenicity of acrylonitrile and evaluation of approaches to pathogenetic correction of acrylate toxicity and antitumorigenic anthracycline doxorubicin toxicity during chemotherapy]. Tarskikh MM, Shumbasov MA, and Kolesnikov SI Vestn. Ross. Akad. Med. Nauk (2), 63-6, (2013)
[Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis]. Filatova LV, Plotnikova AA, Gershanovich ML, et al. Vopr. Onkol. 59(2), 59-65, (2013)
[Organ-specific antitoxic effects of N-stearoylethanolamine in male mice with Lewis carcinoma under doxorubicin intoxication]. Hudz' IeA, Hula NM, Horid'ko TM, et al. Ukr. Biokhim. Zh. 85(2), 45-51, (2013)
Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin. Needham D, Park JY, Wright AM, et al. Faraday Discuss. 161, 515-34; discussion 563-89, (2013)
Poly(ethylene glycol) versus dendrimer prodrug conjugates: influence of prodrug architecture in cellular uptake and transferrin mediated targeting. Aher N, Banerjee S, Bhansali S, et al. J. Biomed. Nanotechnol. 9(5), 776-89, (2013)
Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial. Fisher M and Gore M Value Health 16(4), 507-16, (2013)
Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. Niu ZH, Wang Y, Chun B, et al. Eur. Rev. Med. Pharmacol. Sci. 17(10), 1337-44, (2013)
Unusual case of recurrent extraneural metastatic medulloblastoma in a young adult: durable complete remission with Ewing sarcoma chemotherapy regimen and consolidation with autologous bone marrow transplantation and local radiation. Clement J, Varlotto J, Rybka W, et al. J. Clin. Oncol. 31(19), e316-9, (2013)
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial. Damian S, Celio L, De Benedictis E, et al. Oncology 84(6), 371-7, (2013)
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization. Anne Zuse et al J. Med. Chem. 50, 6059-66, (2007)
2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. Arjun Basnet et al Bioorg. Med. Chem. Lett. 20, 42-7, (2010)
Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Pritam Thapa et al Bioorg. Med. Chem. 18, 2245-54, (2010)
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines. Radha Karki et al Bioorg. Med. Chem. 18, 3066-77, (2010)
2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Pritam Thapa et al Bioorg. Med. Chem. 18, 377-86, (2010)
Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity. Hideaki Yamaguchi et al Eur. J. Med. Chem. 45, 2943-8, (2010)
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety. Holger C Nickel et al Eur. J. Med. Chem. 45, 3420-38, (2010)
Design, synthesis and biological evaluation of 3,5-diaryl-isoxazoline/isoxazole-pyrrolobenzodiazepine conjugates as potential anticancer agents. Ahmed Kamal et al Eur. J. Med. Chem. 45, 3924-37, (2010)
Minigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription. Luke D Jasenosky et al Antimicrob. Agents Chemother. 54, 3007-10, (2010)
An efficient one-pot synthesis of benzothiazolo-4?-anilino-podophyllotoxin congeners: DNA topoisomerase-II inhibition and anticancer activity. Ahmed Kamal et al Bioorg. Med. Chem. Lett. 21, 350-3, (2011)
Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase II? catalytic inhibitor. Kyu-Yeon Jun et al Eur. J. Med. Chem. 46, 1964-71, (2011)
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base. I Kraicheva et al Bioorg. Med. Chem. 20, 117-24, (2012)
Aldrich MSDS 1, 849:A / Corp MSDS 1 (1), 1499:A / RegBook 1 (2), 1691:D / Sax 6, 144 / Structure Index 1, 268:B:6
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?